QNRX Stock — Quoin Pharmaceuticals Ltd.: Cash, EV, Pipeline

Share price

$7.06

Market cap

$14.2M

Cash

$10.8M

Enterprise value

$3.4M

Balance sheet

Cash	$10.8M
Debt	$0.0M
Net cash	$10.8M
Enterprise value	$3.4M
Basic shares	70.3M shares
Fully diluted shares	71.3M shares
Fully diluted market cap	$503.5M
Cash per share	$0.15

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading QNRX daily closes…

Loading price history…

Pipeline assets

QRX003

Phase 3 · Active Modality: topical lotion

Aliases QYLEKI (conditionally FDA-approved brand name)

Target kallikreins

Partnerships Skinvisible Pharmaceuticals: exclusive royalty-bearing license (QRX003, QRX004); 9 commercial partnerships spanning 61 countries outside core territories (US, Western Europe, Japan)

Indications

Netherton Syndrome (Phase 3)
Peeling Skin Syndrome (Phase 2)

Catalysts

— H2 2026

Status note Pivotal registrational Phase 3 under open FDA IND enrolling. FDA Fast Track (March 2026); Japan MHLW Orphan Drug Designation (June 2026). Compassionate use program in 8 pediatric patients.

QRX009

Preclinical · Active Modality: topical formulation

Partnerships University College Cork (UCC): research agreement for novel topical rapamycin formulations

Indications

Pachyonychia Congenita (Preclinical)
Gorlin Syndrome (Preclinical)
Tuberous Sclerosis Complex (Preclinical)
Microcystic lymphatic malformations (Preclinical)
Venous malformations (Preclinical)
Angiofibromas (Preclinical)

Catalysts

— Q3 2026

Status note Topical rapamycin (sirolimus). Investigator-led clinical studies planned in Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex.

QRX008

Preclinical · Active

Target VLA-4

Partnerships Queensland University of Technology (QUT): research agreement; option for a global license (Netherton Syndrome research with QUT discontinued July 2025)

Indications

Scleroderma (Preclinical)

Status note Preclinical research program; company has option for global license.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Ikarian Capital	211,538	no change	0.17%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

QNRX — Quoin Pharmaceuticals Ltd.

Balance sheet

Price history

Pipeline assets

Institutional holders